Geron Corporation Common Stock (NASDAQ: GERN)
Company Name:Geron Corporation Common Stock
Stock Symbol:NASDAQ: GERN
Class Period Start:03/19/2018
Class Period End (inclusive):09/26/2018
According to the Complaint, Geron Corporation is a biopharmaceutical company with its headquarters located in Menlo Park, California.
The Complaint alleges that throughout the Class Period, Defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, the Complaint alleges that Defendants: (1) misled investors about the results of a clinical drug study of imetelstat called IMbark; and (2) as a result, Defendants' statements about Geron's business, operations, and prospects were materially false and misleading and lacked a reasonable basis at all relevant times.